Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab oral - Biora Therapeutics

Next Previous
Search
Drug Profile

Adalimumab oral - Biora Therapeutics

Alternative Names: BT-001 - Biora Therapeutics; BT-002; PGN-001; PGN-OB1

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Progenity
  • Developer Biora Therapeutics
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders
  • No development reported Ulcerative colitis

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Ulcerative-colitis in USA (PO, Capsule)
  • 19 Dec 2023 Biora Therapeutics receives an Issue Notification from the United States Patent and Trademark Office (USPTO) for NaviCap™ Targeted Oral Delivery Platform
  • 04 Aug 2023 Biora Therapeutics has patent protection and multiple patents pending for its oral delivery platforms worldwide

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top